文献速递肝肾功能剂量调整特殊人群用药

Epcoritamab皮下给药在复发或难治性B细胞非霍奇金淋巴瘤中的群体药代动力学

Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.
PubMed 文献 · Clin Pharmacokinet · 2024-12-21

基于两项1/2期试验327例患者的6819个样本,建立群体药代动力学模型。模型可充分描述皮下注射Epcoritamab的药代动力学特征,清除呈非线性,年龄和体重为显著协变量,但按体重、年龄、性别、种族、轻中度肾功能不全或轻度肝功能不全无需调整剂量,免疫原性风险低。

要点

  • 按体重、年龄、性别、种族、轻中度肾功能不全或轻度肝功能不全无需调整Epcoritamab剂量。
  • Epcoritamab清除呈非线性,1.5-48 mg剂量范围内暴露增加比例高于剂量增加比例。
  • 抗药抗体发生率低(4/156,2.6%),且不影响药代动力学。

核心结论

  • 群体药代动力学模型充分描述了复发或难治性B细胞非霍奇金淋巴瘤患者皮下注射Epcoritamab的药代动力学特征。
  • 基于体重、年龄、性别、种族、轻中度肾功能不全或轻度肝功能不全无需调整剂量。
  • 免疫原性风险低,抗药抗体状态不影响药代动力学。

研究设计与样本

  • 基于两项1/2期临床试验(EPCORE NHL-1和EPCORE NHL-3)的群体药代动力学分析。
  • 纳入327例复发或难治性B细胞非霍奇金淋巴瘤患者的6819个可定量药代动力学样本。
  • 探索的皮下Epcoritamab剂量范围为0.004-60 mg,其中298例患者采用获批给药方案。
  • 采用非线性混合效应模型进行分析。

主要发现

  • 模型采用二房室靶点介导药物处置模型的一级吸收准稳态近似。
  • 首次全剂量后中位达峰时间(tmax)为4天,每周给药方案结束时(第3周期末)为2.3天。
  • 年龄和体重为Epcoritamab药代动力学的显著协变量。
  • EPCORE NHL-1中复发或难治性大B细胞淋巴瘤患者表观总分布体积几何均值(CV%)为25.6 L(82%)。
  • 第3周期末48 mg全剂量下表观总清除率和终末半衰期几何均值(CV%)分别为0.53 L/day(40%)和22天(58%)。

关键数值与推荐

  • 获批给药方案:第1周期第1天0.16 mg递增剂量1,第1周期第8天0.8 mg递增剂量2,随后48 mg全剂量,第1-3周期每周一次,第4-9周期每两周一次,之后每4周一次,每周期28天。
  • 年龄和体重为显著协变量,但临床数据分析未发现体重或年龄与疗效或安全性相关。
  • 抗药抗体在156例可评估患者中4例(2.6%)出现,且不影响药代动力学。

临床怎么用

  • 基于体重、年龄、性别、种族、轻中度肾功能不全或轻度肝功能不全无需调整Epcoritamab剂量。
  • 临床使用中无需常规监测抗药抗体对药代动力学的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Epcoritamab is a CD3xCD20 bispecific antibody approved for the treatment of adults with different types of relapsed or refractory (R/R) B cell non-Hodgkin lymphoma (B-NHL) after ≥ 2 lines of systemic therapy. Here we report the first results from a population pharmacokinetic model-based analysis using data from 2 phase 1/2 clinical trials (EPCORE® NHL-1, NCT03625037 and EPCORE NHL-3, NCT04542824) evaluating epcoritamab in patients with R/R B-NHL. METHODS: Plasma concentration-time data included 6819 quantifiable pharmacokinetic samples from 327 patients with R/R B-NHL. A wide range of subcutaneous epcoritamab doses, 0.004-60 mg, was explored, with most patients (n = 298) following the approved dosing regimen: step-up dose (SUD) 1 of 0.16 mg on cycle 1 day 1 and SUD 2 of 0.8 mg on cycle 1 day 8, followed by a full dose of 48 mg administered weekly during cycles 1-3, biweekly in cycles 4-9, and every 4 weeks thereafter. Each cycle lasted 28 days. The data were analyzed using nonlinear mixed-effects modeling. RESULTS: Quasisteady-state approximation of a two-compartment target-mediated drug disposition model with first-order absorption adequately characterized pharmacokinetics of epcoritamab following subcutaneous administration. After the first full dose and at the end of the weekly dosing regimen (end of cycle 3), the estimated median time to maximum concentration (tmax) was 4 and 2.3 days, respectively. Age and body weight were significant covariates on the pharmacokinetics of epcoritamab. The geometric mean (coefficient of variation [CV], %) of the apparent total volume of distribution was 25.6 L (82%) for patients with R/R large B cell lymphoma in EPCORE NHL-1. Epcoritamab elimination exhibited nonlinear characteristics, with exposure increasing more than proportionally over 1.5-48 mg doses. The geometric mean (CV%) values of apparent total clearance and terminal half-life were 0.53 L/day (40%) and 22 days (58%), respectively, at the end of cycle 3 for the 48 mg full dose. Clinical data analyses did not identify any association between assessed characteristics, including body weight or age, and clinical efficacy or safety. After accounting for body weight, no clinically significant differences in epcoritamab pharmacokinetics were observed for sex, race, renal or hepatic function, or other disease characteristics. Age was not found to significantly affect epcoritamab pharmacokinetic exposure. Antidrug antibodies developed in 4 (2.6%) of 156 evaluable patients treated with the approved 0.16/0.8/48 mg regimen. Antidrug antibody status did not affect epcoritamab pharmacokinetics. CONCLUSIONS: Epcoritamab pharmacokinetics in R/R B-NHL were well characterized by the population pharmacokinetic model. No dosage adjustments are recommended in subpopulations based on body weight, age, sex, race, mild-to-moderate renal impairment, or mild hepatic impairment. The risk of immunogenicity was low. These are the first published results of population pharmacokinetic modeling for epcoritamab. Epcoritamab is a medicine used to treat adults with certain forms of large B cell lymphoma after previous treatments have failed. Epcoritamab is a rationally designed protein—a bispecific antibody—that binds to two other proteins: CD3 and CD20. CD3 is present on immune cells called T cells that can be activated to kill cancer cells. CD20 is present on B cells, another type of immune cell. B cells are the major cell type involved in B cell lymphoma. Epcoritamab is injected below the skin rather than into a vein. When a drug will be given to many different patients, it is important to conduct studies that monitor the amount of drug in the blood to make sure the recommended dose is safe and that the patient’s immune system will not remove the drug before it can help the patient. In this study, levels of epcoritamab were measured in the blood of 327 patients who participated in two clinical trials: EPCORE NHL-1 and EPCORE NHL-3. Based on the results of this study, the epcoritamab dose does not need to be changed depending on a patient’s body weight, age, sex, race, mild-to-moderate impairment of kidney function, or mild impairment of liver function. The results also showed that the patient’s immune system is unlikely to reduce the level of epcoritamab in the blood.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Li T, Gibiansky L, Parikh A, et al. Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma. Clin Pharmacokinet. 2024. PMID: 39708278. doi:10.1007/s40262-024-01464-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。